Spago Nanomedical Launches Tumorad(R) Clinical Study: First Step to Fighting Tumors!

Spago Nanomedical AB (publ) is thrilled to announce the upcoming commencement of its clinical phase I/IIa trial, Tumorad-01, utilizing its leading drug candidate 177Lu-SN201. After completing the necessary preparations, the application to kick-off the trial has been successfully submitted to the ethics committee in Australia. All systems are go for the imminent patient enrolment beginning this summer in 2023!

The next step of the application process includes ethical approval from the Australian Human Research Ethics Committee, followed by a Clinical Trial Notification to the Australian Therapeutic Goods Administration. After approval is granted, patient recruitment can begin straight away, offering hope to those in need of treatment.

Spago Nanomedical is delighted to announce the transition of its radionuclide therapy program, Tumorad, into the clinical development phase! The convenient regulatory pathway and financial support of Australia’s R&D costs make it an ideal location for the first clinical trial of the groundbreaking therapy. By summer, the first patient is expected to be enrolled in the study, providing a cost-effective way to bring the life-saving therapy to cancer patients quickly. CEO Mats Hansen is confident that the necessary infrastructure is in place to make Tumorad a success.

Spago Nanomedical is excited to embark on a new clinical trial with 177Lu-SN201 – a potential therapeutic option for those with advanced cancer. This upcoming Phase I/IIa, dose escalation and dose expansion, first-in-human study is designed to evaluate the safety, tolerability and efficacy of 177Lu-SN201 in up to 30 intelligent and courageous patients. Regular updates and detailed information about this study will be available at – so keep a lookout!

Spago Nanomedical’s groundbreaking functional nanoparticles have been clinically proven to selectively accumulate in tumors, demonstrated by the MRI contrast agent SN132D in patients with breast cancer. Promisingly, radionuclide therapies utilizing lutetium-177 (177Lu) and Spago Nanomedical’s advanced polymeric nanomaterial – 177Lu-SN201 – may enable physiologically targeted, tumor-selective treatments for various types of cancer.

Leave a Comment